Pathways to precision medicine in smoking cessation treatments

被引:28
作者
Chen, Li-Shiun [1 ]
Horton, Amy [1 ]
Bierut, Laura [1 ]
机构
[1] Washington Univ, Sch Med, Dept Psychiat, Box 8134,660 S Euclid Ave, St Louis, MO 63110 USA
关键词
Smoking cessation; Precision medicine; Pharmacogenetics; GENOME-WIDE ASSOCIATION; NICOTINE METABOLITE RATIO; LUNG-CANCER RISK; RANDOMIZED CLINICAL-TRIALS; TREATMENT-SEEKING SMOKERS; AFRICAN-AMERICAN SMOKERS; PLACEBO-CONTROLLED TRIAL; CORONARY-ARTERY-DISEASE; GENETIC-VARIATION; CIGARETTE-SMOKING;
D O I
10.1016/j.neulet.2016.05.033
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Cigarette smoking is highly addictive and modern genetic research has identified robust genetic influences on nicotine dependence. An important step in translating these genetic findings to clinical practice is identifying the genetic factors affecting smoking cessation in order to enhance current smoking cessation treatments. We reviewed the significant genetic variants that predict nicotine dependence, smoking cessation, and response to cessation pharmacotherapy. These data suggest that genetic risks can predict smoking cessation outcomes and moderate the effect of pharmacological treatments. Some pharmacogenetic findings have been replicated in meta-analyses or in multiple smoking cessation trials. The variation in efficacy between smokers with different genetic markers supports the notion that personalized smoking cessation intervention based upon genotype could maximize the efficiency of such treatment while minimizing side effects, thus influencing the number needed to treat (NNT) and the number needed to harm. In summary, as precision medicine is revolutionizing healthcare, smoking cessation may be one of the first areas where genetic variants may identify individuals at increased risk. Current evidence strongly suggests that genetic variants predict cessation failure and that cessation pharmacotherapy effectiveness is modulated by biomarkers such as nicotinic cholinergic receptor alpha 5 subunit (CHRNA5) genotypes or nicotine metabolism ratio (NMR). These findings strengthen the case for the development and rigorous testing of treatments that target patients with different biological risk profiles. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:83 / 92
页数:10
相关论文
共 132 条
[1]  
Allenby C. E., 2016, J NEUROIMMUNE PHARM
[2]   Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 [J].
Amos, Christopher I. ;
Wu, Xifeng ;
Broderick, Peter ;
Gorlov, Ivan P. ;
Gu, Jian ;
Eisen, Timothy ;
Dong, Qiong ;
Zhang, Qing ;
Gu, Xiangjun ;
Vijayakrishnan, Jayaram ;
Sullivan, Kate ;
Matakidou, Athena ;
Wang, Yufei ;
Mills, Gordon ;
Doheny, Kimberly ;
Tsai, Ya-Yu ;
Chen, Wei Vivien ;
Shete, Sanjay ;
Spitz, Margaret R. ;
Houlston, Richard S. .
NATURE GENETICS, 2008, 40 (05) :616-622
[3]   Human neuronal acetylcholine receptor A5-A3-B4 haplotypes are associated with multiple nicotine dependence phenotypes [J].
Baker, Timothy B. ;
Weiss, Robert B. ;
Bolt, Daniel ;
von Niederhausern, Andrew ;
Fiore, Michael C. ;
Dunn, Diane M. ;
Piper, Megan E. ;
Matsunami, Nori ;
Smith, Stevens S. ;
Coon, Hilary ;
McMahon, William M. ;
Scholand, Mary B. ;
Singh, Nanda ;
Hoidal, John R. ;
Kim, Su-Young ;
Leppert, Mark F. ;
Cannon, Dale S. .
NICOTINE & TOBACCO RESEARCH, 2009, 11 (07) :785-796
[4]   Nicotine metabolite ratio as a predictor of cigarette consumption [J].
Benowitz, NL ;
Pomerleau, OF ;
Pomerleau, CS ;
Jacob, P .
NICOTINE & TOBACCO RESEARCH, 2003, 5 (05) :621-624
[5]   Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption [J].
Bergen, Andrew W. ;
Michel, Martha ;
Nishita, Denise ;
Krasnow, Ruth ;
Javitz, Harold S. ;
Conneely, Karen N. ;
Lessov-Schlaggar, Christina N. ;
Hops, Hyman ;
Zhu, Andy Z. X. ;
Baurley, James W. ;
McClure, Jennifer B. ;
Hall, Sharon M. ;
Baker, Timothy B. ;
Conti, David V. ;
Benowitz, Neal L. ;
Lerman, Caryn ;
Tyndale, Rachel F. ;
Swan, Gary E. .
PLOS ONE, 2015, 10 (07)
[6]   Nicotinic acetylcholine receptor variation and response to smoking cessation therapies [J].
Bergen, Andrew W. ;
Javitz, Harold S. ;
Krasnow, Ruth ;
Nishita, Denise ;
Michel, Martha ;
Conti, David V. ;
Liu, Jinghua ;
Lee, Won ;
Edlund, Christopher K. ;
Hall, Sharon ;
Kwok, Pui-Yan ;
Benowitz, Neal L. ;
Baker, Timothy B. ;
Tyndale, Rachel F. ;
Lerman, Caryn ;
Swan, Gary E. .
PHARMACOGENETICS AND GENOMICS, 2013, 23 (02) :94-103
[7]   Catechol-O-methyltransferase (COMT) gene variants predict response to bupropion therapy for tobacco dependence [J].
Berrettini, Wade H. ;
Wileyto, E. Paul ;
Epstein, Leonard ;
Restine, Stephanie ;
Hawk, Larry ;
Shields, Peter ;
Niaura, Ray ;
Lerman, Caryn .
BIOLOGICAL PSYCHIATRY, 2007, 61 (01) :111-118
[8]   Variants in nicotinic receptors and risk for nicotine dependence [J].
Bierut, Laura Jean ;
Stitzel, Jerry A. ;
Wang, Jen C. ;
Hinrichs, Anthony L. ;
Grucza, Richard A. ;
Xuei, Xiaoling ;
Saccone, Nancy L. ;
Saccone, Scott F. ;
Bertelsen, Sarah ;
Fox, Louis ;
Horton, William J. ;
Breslau, Naomi ;
Budde, John ;
Cloninger, C. Robert ;
Dick, Danielle M. ;
Foroud, Tatiana ;
Hatsukami, Dorothy ;
Hesselbrock, Victor ;
Johnson, Eric O. ;
Kramer, John ;
Kuperman, Samuel ;
Madden, Pamela A. F. ;
Mayo, Kevin ;
Nurnberger, John, Jr. ;
Pomerleau, Ovide ;
Porjesz, Bernice ;
Reyes, Oliver ;
Schuckit, Marc ;
Swan, Gary ;
Tischfield, Jay A. ;
Edenberg, Howard J. ;
Rice, John P. ;
Goate, Alison M. .
AMERICAN JOURNAL OF PSYCHIATRY, 2008, 165 (09) :1163-1171
[9]  
Bloom A Joseph, 2014, Ann Am Thorac Soc, V11, P1003, DOI 10.1513/AnnalsATS.201401-010OC
[10]   Use of a predictive model derived from in vivo endophenotype measurements to demonstrate associations with a complex locus, CYP2A6 [J].
Bloom, A. Joseph ;
Harari, Oscar ;
Martinez, Maribel ;
Madden, Pamela A. F. ;
Martin, Nicholas G. ;
Montgomery, Grant W. ;
Rice, John P. ;
Murphy, Sharon E. ;
Bierut, Laura J. ;
Goate, Alison .
HUMAN MOLECULAR GENETICS, 2012, 21 (13) :3050-3062